Would you consider using acetazolamide to manage glomerular hyperfiltration in patients with type 1 diabetes, since SGLT2 inhibitors are contraindicated in this population?

Clever idea, but I think it is a bit much to assume that increased Na delivery from carbonic anhydrase blockade proximally would have the same renoprotective effect as an SGLT2i. So, no, I would not do this. However, I admire anyone thinking outside the box!

I would probably not jump to use acetazolamide in type 1 diabetes based on this study. I would want to see more data on effect on proteinuria, electrolytes, and GFR over time. Too preliminary but something to explore.